HCM
WST icon

Hilton Capital Management’s West Pharmaceutical WST Stock Holding History

Hilton Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.43M Buy
17,923
+880
+5% +$269K 0.44% 62
2026
Q1 		$4.27M Buy
17,043
+6,776
+66% +$1.69M 0.32% 75
2025
Q4 		$2.82M Buy
10,267
+992
+11% +$271K 0.21% 105
2025
Q3 		$2.43M Buy
9,275
+472
+5% +$115K 0.2% 102
2025
Q2 		$1.93M Buy
8,803
+4,021
+84% +$860K 0.15% 113
2025
Q1 		$1.07M Buy
4,782
+524
+12% +$144K 0.09% 125
2024
Q4 		$1.39M Buy
4,258
+195
+5% +$61.4K 0.12% 115
2024
Q3 		$1.22M Buy
+4,063
New +$1.24M 0.09% 123
2024
Q2 		– Sell
-5,080
Closed -$2.01M – 180
2024
Q1 		$2.01M Buy
5,080
+2,824
+125% +$1.04M 0.18% 88
2023
Q4 		$794K Buy
+2,256
New +$798K 0.09% 82
2023
Q3 		– Sell
-639
Closed -$244K – 137
2023
Q2 		$244K Buy
+639
New +$228K 0.03% 94

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hilton Capital Management's WST Position: Q2 2026 in Review

Hilton Capital Management increased its West Pharmaceutical (WST) stake by 5.2% in Q2 2026, buying an estimated $269K and bringing the position to 17,923 shares worth $6.43M. The position accounts for 0.44% of the portfolio, ranked #62.

Hilton Capital Management first reported a position in WST in Q2 2023 and has held it in 11 quarters since. 832 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Hilton Capital Management held 17,923 shares of West Pharmaceutical worth $6.43M as of Q2 2026.
  • Hilton Capital Management bought 880 West Pharmaceutical shares in Q2 2026, an estimated $269K.
  • West Pharmaceutical made up 0.44% of Hilton Capital Management's portfolio in Q2 2026, its #62 holding.
  • Hilton Capital Management first reported a position in West Pharmaceutical in Q2 2023 and has held it in 11 quarters since.
  • 832 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Hilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.